display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 1st line (L1)
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC CheckMate 9DW

Study type: